Top Markets
Coin of the day
AIkido Pharma Inc. AIkido Pharma Inc.

AIkido Pharma Inc.

AIKI
Rang in Aktien #30001
AIkido Pharma Inc., established in 1967 and headquartered in New York, New... AIkido Pharma Inc., established in 1967 and headquartered in New York, New York, is a biotechnology company primarily engaged in pioneering small-molecule anti-cancer treatments. The firm, which operated as Spherix Incorporated until its rebranding in March 2021, possesses a robust therapeutic pipeline addressing various malignancies, including prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. Key drug candidates in its development portfolio include DHA-dFdC, targeting pancreatic cancer, and KPC34, a small molecule designed for the treatment of both AML and acute lymphoblastic leukemia. Furthermore, AIkido Pharma Inc. is advancing an antiviral platform engineered to hinder the proliferation of numerous viruses, such as the influenza virus, Ebolavirus, Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. The company holds strategic license agreements with several academic and research institutions, including the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences.
Aktienkurs
$3.56
Zuletzt synchronisiert: 2022-12-21
Marktkapitalisierung
$18.70M
Veränderung (1 Tag)
0.28%
Veränderung (1 Jahr)
0.00%
Land
US
Handel AIkido Pharma Inc. (AIKI)

Kategorie

Kursverlauf für AIkido Pharma Inc. (AIKI)
Höchster Schlusskurs: $3.56 am 2022-12-01

Niedrigster Schlusskurs: $11.43 am 2020-03-01
Kursverlauf der Aktie von AIkido Pharma Inc. von 2020 bis 2026
Jährliche Kursentwicklung
Jahr Leistung
2022 -68.17%
2021 0.42%
2020 0.00%
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Aktienkurs Veränderung 1J% Land
$527.89 35.09%
US
$996.61 51.72%
NL
$117.42 -19.34%
AU
$735.86 6.07%
CH
$1.07K -5.58%
KR